Healthcare entity

MarketBeat

Company

MarketBeat is most often covered alongside Weiss Ratings, which appears in 2 of these 4 stories. Across a 35-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. Each story carries 1.8 original sources on average, compared with 3.5 for the broader beat in this window.

Last mentioned: 3d ago

Entity pulse

Recent coverage · MarketBeat

4 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about MarketBeat

MarketBeat is most often covered alongside Weiss Ratings, which appears in 2 of these 4 stories. Across a 35-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. Each story carries 1.8 original sources on average, compared with 3.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6 for that window. medical-devices accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. This profile follows 4 Healthcare stories mentioning MarketBeat across the period from July 10, 2026 to August 13, 2026.

Stories tracked
4
Per week
0.8
Sources per story
1.8

Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 351 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering MarketBeat. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning MarketBeat 4

Medical Devices Neutral

Renuvion Maker Apyx Drops 1.8% to $4.38 Despite Q1 Revenue Beat

For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.

2 sources

MarketBeat is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.